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Diffuse low-grade gliomas (LGG) of World Health Organization 
grade II are a heterogeneous group of CNS tumors whose natu-
ral history depends primarily on patient age, histological type, 
and molecular characteristics. The optimum initial management 
is maximal safe resection, while the choice and timing of adju-
vant therapies (ie, radiotherapy and/or chemotherapy in high-
risk patients) are still a matter of discussion. Radiotherapy has 
long been considered the standard treatment, but the docu-
mented activity of alkylating chemotherapy, either the com-
bination of procarbazine, lomustine, and vincristine (PCV) or 
temozolomide, along with concerns about the risk of late cog-
nitive defects from radiotherapy, have led many clinicians to 
postpone the use of radiotherapy at tumor progression in favor 
of initial chemotherapy alone.1 Recent large molecular stud-
ies2 have shown that low and intermediate-grade gliomas can 
be subdivided into 3 groups with different prognoses based on 
molecular markers (ie, groups with isocitrate dehydrogenase 
(IDH) 1 or 2 mutations and 1p/19q codeletion; IDH 1 or 2 muta-
tions and no 1p/19q codeletion; and IDH 1 and 2 wild type). Thus, 
there is an obvious need to validate such a categorization in pro-
spective trials.
In this issue of Neuro-Oncology, Wahl and coworkers3 have 
reported the long-term results of a single-arm, phase II trial 
investigating the efficacy of primary temozolomide in an insti-
tutional cohort of patients with newly diagnosed LGG and 
evaluable residual disease on postoperative MRI, and have 
analyzed the clinical results based on molecular subtypes. One 
hundred and twenty patients were enrolled between 2000 and 
2013 with a median follow-up of 7.5 years, and in 97 patients 
tissue was available for molecular analysis. The primary end-
point of the study was the objective response rate based on 
measurement of tumor area. The authors observed a relatively 
low rate of partial responses (6%) compared with the values 
(10%–20%) reported in previous smaller prospective studies, 
employing temozolomide either in standard or dose-dense 
schedules. However, they did not differentiate on MRI the 
minor response from stable disease, as it is now codified in the 
Response Assessment in Neuro-Oncology criteria.4 It must be 
said that the evaluation on standard MRI of response following 
antineoplastic drugs is still a major problem in nonenhancing 
tumors, such as most LGG. Volumetric measurements on MRI,4 
assessment of 2-hydroxyglutarate in IDH-mutated gliomas by 
MR spectroscopy,5 and/or metabolic evaluations by PET with 
amino acids6 could provide a better insight, but all need vali-
dation in large homogeneous prospective cohorts of patients. 
Wahl and colleagues reported a median progression-free sur-
vival (PFS) of 3.8 years and a median overall survival (OS) of 
9.7  years. In 2016 two phase III trials on adjuvant treatment 
of high-risk LGG have been published. The phase III Radiation 
Therapy Oncology Group (RTOG) study 9802 reported a signifi-
cant advantage of adding PCV chemotherapy to radiotherapy 
in terms of PFS (10.4 y vs 4.0 y) and OS (13.3 y vs 7.8 y).7 The 
phase III European Organisation for Research and Treatment 
of Cancer (EORTC) study 22033 did not find significant differ-
ences in terms of PFS between-dose dense temozolomide and 
radiotherapy (39 mo vs 46 mo) as initial adjuvant treatment,8 
while data on OS are not mature due to a relatively short fol-
low-up. The comparison between the survival figures of these 
trials allows some considerations. First, median PFS of patients 
receiving temozolomide alone was similar in the Wahl study 
and in the EORTC study (3.8 y and 3.2 y, respectively), but also 
similar to that of patients receiving radiotherapy alone in the 
EORTC and RTOG trials (3.8 y and 4.0 y, respectively). These 
findings could suggest that temozolomide and radiotherapy are 
comparable in terms of clinical efficacy when employed as ini-
tial treatment. Conversely, the value of PFS for patients receiv-
ing radiotherapy plus PCV in RTOG 9802 is clearly superior 
(10.4 y). Thus, it is clear that, if choosing radiotherapy as adju-
vant treatment following an incomplete resection, PCV must 
be added. The next question now is whether a salvage radio-
therapy at relapse after initial chemotherapy alone will bring 
the same OS obtained with radiotherapy plus PCV. Thus far, 
the median OS reported by Wahl and colleagues (9.7 y) seems 
still shorter than that of RTOG 9802 (13.3 y). Overall, the unan-
swered question is whether a relatively shorter survival follow-
ing upfront chemotherapy alone compared with radiotherapy 
followed by chemotherapy is balanced by a better preservation 
of cognitive functions and quality of life: in this respect, there 
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is lack of information, and new studies need to incorporate 
a serial monitoring of cognitive functions over many years 
of follow-up. Regarding the choice between temozolomide 
and PCV, especially for combination with radiotherapy, we 
lack data suggesting that temozolomide, which has a better 
toxicity profile, is as effective as PCV in LGG. In this regard, 
the single-arm phase II RTOG 0424,9 investigating radio-
therapy plus concomitant/adjuvant temozolomide in high-
risk patients has reported a median PFS of 4.5 years, which 
is by far inferior to that of RTOG 9802 (10.4 y) with radio-
therapy plus PCV. However, in RTOG 0424 compared with 
RTOG 9802 there was an excess of astrocytomas (55% vs 
23%–29%), which are considered less prone to respond to 
chemotherapy than oligodendrogliomas. Future clinical tri-
als, such as the newly developed CODEL trial, will hopefully 
clarify the role of chemoradiation in high-risk LGG.
Interestingly, more than half of the patients did not 
receive radiotherapy with a long follow-up (median 5.8 y), 
and the rate of malignant transformation following temo-
zolomide was not higher than that reported in the general 
population of LGG. Most important, the authors observed 
that no 1p/19q codeleted patients progressed during treat-
ment compared with more than half of IDH 1 wild-type 
patients, and this strongly influenced the OS (9.7 y vs 1.8 
y). These data are in line with those recently reported by 
the EORTC study. Whether patients with 1p/19q codele-
tion are candidates for chemotherapy alone or observa-
tion with MRI following an incomplete resection is to be 
clarified.
Another open issue is whether the recently reported 
temozolomide-induced hypermutagenesis10 can increase 
the aggressiveness of some molecular subtypes of tumors 
and negatively impact the outcome.
Future trials on LGG will need a prospective collection 
of information on changes of seizure activity during treat-
ment,11 as in a large proportion of patients seizures are the 
unique symptom.
In conclusion, even if the trial by Wahl et al did not meet 
the primary endpoint (response rate), it represents the 
largest prospective study on upfront chemotherapy with 
temozolomide in high-risk patients with LGG, as defined 
by incomplete resection, who were stratified by molecu-
lar factors of prognostic significance. Their results must be 
considered hypothesis generating and need confirmation 
in well-designed clinical trials.
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